Adagio Medical Holdings, Inc.
ADGMHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeAdagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. The $9.8M market capitalization puts ADGM squarely in micro-cap range for its industry. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia.
Market Cap
$9.8M
Beta
-0.19
P/E (TTM)
—
P/E (Fwd)
-0.33
EPS (TTM)
$-1.14
EPS (Fwd)
$-1.35
ROE
-268.9%
ROA
-30.5%
Cash
$12.9M
Total Debt
$24.1M
Free CF
-$7.6M
52W Change
-73.9%
Annual Financials
Cash vs Debt
Where ADGM stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ADGM finished 40.21% below its 150-day moving average ($0.97) and 45.28% below its 200-day moving average ($1.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADGM overbought or oversold?
At the July 15, 2026 close, ADGM's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $12.9M in cash, though total debt stands at $24.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$7.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -268.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $270K (2021) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Adagio Medical Holdings, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Adagio Medical Holdings, Inc. and its sector.